What are the side effects of Monjaro (tirzepatide)?

Side Effects of Monjaro (Tirzepatide)

The most common side effects of Monjaro are gastrointestinal in nature—primarily nausea, diarrhea, vomiting, decreased appetite, constipation, and indigestion—which occur in a dose-dependent manner and are typically mild to moderate, occurring mainly during dose escalation. 1

Common Side Effects (Frequency and Pattern)

Gastrointestinal Effects (Most Frequent)

The gastrointestinal side effects follow a predictable pattern 2:

• Nausea: Affects approximately 20-39% of patients (dose-dependent: 35% at 5mg, 42% at 10mg, 49% at 15mg) 3, 4
• Diarrhea: Occurs in approximately 16-20% of patients 1, 4
• Vomiting: Affects about 9% of patients 4
• Decreased appetite: Occurs in approximately 10% of patients 4
• Constipation: Affects about 2.5% of patients 4
• Indigestion and abdominal pain: Common complaints 1

Critical timing: 70-80% of GI side effects occur within the first 2 weeks of treatment, 75-80% are mild in severity, and 60-65% resolve within the first month 2. This makes slow dose titration essential to minimize these effects.

Other Common Side Effects

• Injection site reactions 2
• Elevated heart rate 2
• Esophageal reflux 2

Serious but Rare Side Effects (≤1%)

Pancreatitis

Pancreatitis has been reported in clinical trials, though causality has not been definitively established 2. Discontinue Monjaro immediately if pancreatitis is suspected—specifically if severe abdominal pain that won't resolve occurs, with or without vomiting, potentially radiating to the back 1. The incidence remains extremely low (≤1%) across all doses 3.

Gallbladder Disease

• Cholelithiasis and cholecystitis: May occur, with rates ≤1% 2, 3
• Warning signs: Upper abdominal pain, fever, jaundice, or clay-colored stools 1

Kidney Problems

In patients with pre-existing kidney disease, the GI side effects (diarrhea, nausea, vomiting) can cause dehydration, potentially worsening kidney function or causing acute kidney injury 2, 1. Use caution when initiating or escalating doses in patients with kidney disease 2.

Hypoglycemia

• Risk is low when used alone but increases significantly when combined with insulin or sulfonylureas 1
• Incidence of mild hypoglycemia (blood glucose <70 mg/dL) peaks at approximately 23% with the 10mg dose when combined with other glucose-lowering agents 3
• Severe hypoglycemia remains rare (≤1%) 3
• Symptoms to monitor: dizziness, sweating, confusion, headache, blurred vision, shakiness, fast heartbeat 1

Thyroid C-Cell Tumors (Black Box Warning)

Monjaro carries a black box warning for risk of thyroid C-cell tumors, based on rodent studies where medullary thyroid carcinoma developed 2, 1. Human relevance has not been determined. Contraindicated in patients with personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) 1.

Warning signs: Lump or swelling in neck, hoarseness, trouble swallowing, or shortness of breath 1.

Dose-Dependent Effects

Drug discontinuation due to adverse events increases with dose: approximately 10% at the 15mg dose 3. The gastrointestinal adverse events show clear dose-dependency, increasing from 39% at 5mg to 49% at 15mg 3.

Special Considerations and Drug Interactions

Delayed Gastric Emptying

Monjaro slows gastric emptying, which has important implications 5:

• Increased aspiration risk during surgery or procedures requiring anesthesia—inform all healthcare providers before any procedure 1
• Oral contraceptive efficacy may be reduced: Switch to non-oral contraception or add barrier method for 4 weeks after initiation and 4 weeks after each dose escalation 2, 6
• Monitor medications with narrow therapeutic index (e.g., warfarin) 2

Gastrointestinal Disorders

Severe constipation, small bowel obstruction, and ileus progression have been reported 2. Stop Monjaro if severe stomach problems occur that don't resolve 1.

Vision Changes

Diabetic retinopathy complications may occur; report any vision changes during treatment 1.

Allergic Reactions

Serious allergic reactions are rare but require immediate discontinuation 1:

• Swelling of face, lips, tongue, or throat
• Problems breathing or swallowing
• Severe rash or itching
• Fainting, dizziness, or very rapid heartbeat

Clinical Pitfalls to Avoid

1. Inadequate dose titration: Rapid escalation increases GI side effects. Follow manufacturer's titration schedule strictly.
2. Ignoring dehydration risk: Elderly patients and those with kidney disease are particularly vulnerable to dehydration from GI effects 2.
3. Combining with high-risk medications: When used with insulin or sulfonylureas, hypoglycemia risk increases substantially—dose adjustments of these agents are typically needed 1.
4. Inadequate contraception counseling: Failure to address oral contraceptive interactions can lead to unintended pregnancy 2, 6.
5. Proceeding to surgery without proper communication: The aspiration risk necessitates informing anesthesia providers 5, 1.